Publication date: Apr 09, 2019
Aberrant RNA structure and function operate in neurological disease progression and severity. As RNA contributes to disease pathology in a complex fashion, that is, via various mechanisms, it has become an attractive therapeutic target for small molecules and oligonucleotides. In this review, we discuss the identification of RNA structures that cause or contribute to neurological diseases as well as recent progress toward the development of small molecules that target them, including small molecule modulators of pre-mRNA splicing and RNA repeat expansions that cause microsatellite disorders such as Huntington’s disease and amyotrophic lateral sclerosis. The use of oligonucleotide-based modalities is also discussed. There are key differences between small molecule and oligonucleotide targeting of RNA. The former targets RNA structure, while the latter prefers unstructured regions. Thus, some targets will be preferentially targeted by oligonucleotides and others by small molecules.
Angelbello, A.J., Chen, J.L., and Disney, M.D. Small molecule targeting of RNA structures in neurological disorders. 06440. 2019 Ann N Y Acad Sci.
|disease||DOID||amyotrophic lateral sclerosis|
|disease||MESH||amyotrophic lateral sclerosis|